Breast Cancer Drugs Market To Be Worth $19.96bn In 2020, New Visiongain Analysis Predicts

10 September 2018
Pharma

A new visiongain report forecasts that the global breast cancer drugs market will generate $19.96 billion in 2020. That revenue forecast and many others appear in Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals, published in March 2016. Visiongain is a business information publisher and consultancy based in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Breast cancer is the second most common cancer in the world, and by far the most common cancer among women. With the prevalence of the disease set to increase, a strong pipeline waiting to be launched, and the rising use of combination therapies to benefit both patients and manufacturers, we expect strong growth for this lucrative market.

“However, the breast cancer drugs market will also have to face patent expiries for various leading therapies during the forecast period and the looming threat of generic and biosimilar erosion, amongst other difficult challenges. As such, 2016-2026 is a crucial period for this market, one which will determine its long term future.”

Visiongain’s new analysis provides revenue forecasts for the global breast cancer drugs market from 2016 to 2026.

That study also gives revenue forecasts, specifically for the breast cancer indication, for nine leading drugs from 2016 to 2026:

• Herceptin (trastuzumab), Roche
• Perjeta (pertuzumab), Roche
• Afinitor (everolimus), Novartis
• Faslodex (fulvestrant), AstraZeneca
• Ibrance (palbociclib), Pfizer
• Avastin (bevacizumab), Roche
• Kadcyla (ado-trastuzumab emtansine), Roche
• Femara (letrozole), Novartis
• Abraxane (paclitaxel Protein-Bound), Celgene.

That investigation also provides overall forecasts for two classes of biosimilar: trastuzumab and bevacizumab.

The report also divides the overall market into its main therapeutic segments, showing revenue forecasts from 2016 to 2026 for these four submarkets:

• Monoclonal antibodies (mAbs)
• Chemotherapy and hormone therapy
• Kinase inhibitors
• Other medicines.
That work also assesses the current status of 18 of the most promising candidates in research and development. It also shows interviews with two companies. In addition, visiongain’s study provides revenue forecasts for 11 national breast cancer drug markets:

• The United States
• Japan
• Germany, France, Italy, the United Kingdom and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group).

Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

Read

Visiongain Publishes Inhalation & Nasal Spray Generic Drugs Market Report 2021-2031

Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.

31 March 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever